A study of PMN-310 for Alzheimer's disease
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2017
At a glance
- Drugs PMN 310 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 13 Sep 2017 According to a ProMIS Neurosciences media release, the molecule PMN310 is on track for initiation of clinical trials in 2019.
- 05 Apr 2017 New trial record
- 30 Mar 2017 According to a ProMIS Neurosciences media release, the company expects to file an Investigational New Drug application and initiate the trial in late 2018.